Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2012 Feb;18(2):110-8.
doi: 10.1111/j.1755-5949.2010.00225.x. Epub 2010 Dec 28.

Description of study population and analysis of factors influencing adherence in the observational Italian study "Evaluation of Pharmacotherapy Adherence in Bipolar Disorder" (EPHAR)

Collaborators, Affiliations
Multicenter Study

Description of study population and analysis of factors influencing adherence in the observational Italian study "Evaluation of Pharmacotherapy Adherence in Bipolar Disorder" (EPHAR)

Alessandra Barraco et al. CNS Neurosci Ther. 2012 Feb.

Abstract

Background: In patients with bipolar disorder, medication is effective in preventing relapses. Unfortunately, adherence to treatment in bipolar disorder, as in other chronic or recurrent conditions, is not optimal. Estimates of nonadherence to prescribed treatment range from 30% to 60% in epidemiological studies, and are at around 30% in clinical trials. Adherence to treatment is a potent predictor of effectiveness, both in clinical trials and cohort studies, therefore is a very relevant area of investigation. This study will try to show a picture of the real life care where adherence is influenced by a wide range of variables.

Methods: Prospective, observational, multicenter study in 650 adult patients with bipolar disorder, who had to initiate or change their treatment regimen, observed for 1 year. Adherence was measured by the Simplified Medication Adherence Questionnaire (SMAQ). Additional variables: Symptom severity, Montgomery-Åsberg Depression Rating Scale (MADRS), Young Mania Rating Scale (YMRS), Clinical Global Impression-Bipolar Disorder (CGI-BD), the Drug Attitude Inventory score (DAI-30), and quality of life (EuroQoL 5 Dimensions). The variables were recorded every 3 months for the next year.

Results: Most subjects were out-patients (77.1%), female (58.8%), aged 31-50 years (50.1%) and overweight (41.8%) or obese (28.7%); 67.4% had type I bipolar disorder and 66.8% had depressive or mixed symptoms. Adherence was 39.9% at baseline (and increased up to 67.0% at completion. The main predictors of nonadherence were alcohol consumption, severe bipolar symptoms, young age at time of first treatment, negative attitude towards treatment.

Conclusions: The patient population of this observational trial was representative of the patients changing their therapy for bipolar disorder seen in clinical practice in Italy. Lack of adherence to pharmacotherapy for bipolar disorder is a serious issue, which is more likely to arise in alcohol users and patients with severe symptoms, negative attitude towards medication and/or initiation of treatment early in life. The findings could lead to a more adequate approach of adherence in patients with bipolar disorders.

PubMed Disclaimer

Conflict of interest statement

Alessandra Barraco and Andrea Rossi are employees of Eli Lilly Italia.

Figures

Figure 1
Figure 1
Patients disposition.
Figure 2
Figure 2
Percentage of patients adherent to prescribed pharmacological treatment for bipolar disorder measured by SMAQ.

Similar articles

Cited by

References

    1. Goetzel RZ, Hawkins K, Ozminkowski RJ, Wang S. The health and productivity cost burden of the “top 10” physical and mental health conditions affecting six large U.S. employers in 1999. J Occup Environ Med 2003;45:5–14. - PubMed
    1. Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: Follow‐up over 34–38 years. J Affect Disord 2002;68:167–181. - PubMed
    1. Schou M. The combat of non‐compliance during prophylactic lithium treatment. Acta Psychiatr Scand 1997;95:361–363. - PubMed
    1. Guscott R, Taylor R. Lithium prophylaxis in recurrent affective illness. Efficacy, effectiveness and efficiency. Br J Psychiatry 1994;164:741–746. - PubMed
    1. Scott J. Predicting medication non‐adherence in severe affective disorders. Acta Neurolopsychiatr 2000;12:128–130. - PubMed

Publication types